33 results
10-K
2023 FY
EX-3.6
GYRE
Gyre Therapeutics Inc
Annual report
27 Mar 24
4:31pm
8-K
EX-3.2
GYRE
Gyre Therapeutics Inc
30 Oct 23
Entry into a Material Definitive Agreement
5:17pm
8-K
EX-3.1
GYRE
Gyre Therapeutics Inc
30 Oct 23
Entry into a Material Definitive Agreement
5:17pm
8-K
EX-3.3
GYRE
Gyre Therapeutics Inc
30 Oct 23
Entry into a Material Definitive Agreement
5:17pm
8-K
EX-3.1
GYRE
Gyre Therapeutics Inc
31 Aug 23
Entry into a Material Definitive Agreement
4:17pm
DEFA14A
EX-3.1
v6tlwtjj 3bwnm39
20 Jun 23
Additional proxy soliciting materials
5:02pm
8-K
EX-3.1
2sl6uhrutmb4cz750kz
20 Jun 23
Material Modifications to Rights of Security Holders
5:00pm
425
EX-3.1
gck 3a8ao13
27 Dec 22
Business combination disclosure
7:02am
425
EX-3.2
7uvwve
27 Dec 22
Business combination disclosure
7:02am
8-K
EX-3.2
8uny96s6i7qjmnx82no
27 Dec 22
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
7:00am
8-K
EX-3.1
p8nnpdda0ekpqd
27 Dec 22
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
7:00am
8-K
EX-3.1
5ebwi7n m1q
16 Jun 20
Catalyst Biosciences Appoints Clinton Musil as Chief Financial Officer
12:00am
8-K
EX-3.1
aiqdep tb
13 Apr 17
Catalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering
12:00am
8-K
EX-3.1
q3iza sgcrfu
10 Feb 17
Catalyst Biosciences Announces1-for-15 Reverse Stock Split
12:00am
8-K
EX-3.1
uryce0lck7xas
20 Aug 15
Catalyst Biosciences Completes Merger with Targacept and Creates a Protease-Based
12:00am
8-K
EX-3.1
vtqrtis j3adbto
6 Mar 15
Targacept and Catalyst Biosciences Enter Definitive Merger Agreement Creating a Protease-Based Hemostasis and Anti-Complement Company
12:00am
425
EX-3.1
xu0g338mpzp
6 Mar 15
Business combination disclosure
12:00am
8-K
EX-3.1
p4m9rpewt6itcq
11 Aug 09
Amendments to Articles of Incorporation or Bylaws
12:00am